Investor Centre

PXS-5505 Multinational Trial in Myelofibrosis Cleared by Safety Committee to Advance to Second Stage of Dose Escalation Study.

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced it has completed dosing the first of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. The study’s safety monitoring committee that advises on the study progress, has given the green light to progress to the second dose level after reviewing factors including the safety and pharmacokinetic properties of PXS-5505 in myelofibrosis patients.